Bu Puspa was diagnosed with adenocarcinoma of the breast in 2013. She refused chemotherapy and surgery, opting instead for an alternative treatment using the ECCT device, even though it was entirely new at the time. She approached the treatment with great care and diligence, closely monitoring her therapy’s progress. She achieved remission after three years of using the device. However, the lump reappeared during the pandemic after receiving the vaccine.
Right: Mammogram results before and initial ultrasound; Center: PET-CT scan results after 1.5 years of use and ultrasound showing clear results after three years; Left: Photo of Bu Puspa after 10 years cancer-free.
At the end of 2013, Bu Puspa felt a lump in her right breast, approximately the size of a ping-pong ball. An ultrasound showed the lump measured about 3 cm, and a biopsy revealed it to be a highly malignant adenocarcinoma. In addition to the malignant lump in her right breast, there was also a small cyst in her left breast, measuring less than 1 cm. Following standard medical procedure, her doctor recommended surgery and chemotherapy.
However, Bu Puspa was determined not to undergo chemotherapy or surgery. She insisted on using the ECCT device, hoping to avoid surgery or chemotherapy. It was a bold decision, considering the device was still very new. But the prospect of overcoming breast cancer without surgery was extraordinary for a woman facing this disease.
She received an ECCT device in the form of a vest and a smaller attachment for the underarm to prevent cancer from spreading to the lymph nodes. Bu Puspa began using the ECCT in early December 2013, wearing it for 12 hours a day, five days a week, rarely missing a session, no matter where she was.
Bu Puspa’s therapy went smoothly. Like other ECCT users, she experienced detox reactions such as strong-smelling sweat, urine, and dark, foul-smelling bowel movements. These reactions lasted for several months.
Her cancer type, classified as Group B, responded well to the ECCT therapy, showing relatively quick progress. Group B cancers are easily broken down by exposure to electric fields, and the dead cells, which are soft and fluid, are easily expelled through sweat, urine, and feces. Medically, this is considered an aggressive type of cancer, but it responds quickly to electrical therapy.
With the older ECCT device, tumors measuring 2-3 cm typically dissolve over two to three years without surgery. The latest version of the ECCT device can dissolve similar tumors in just three to six months.
Tumor shrinkage in breast cancer depends not only on the cancer type but also on the drainage channels near the tumor site that carry the dead cells through the bloodstream to the body’s main disposal systems (sweat, urine, and feces).
For breast cancer, the drainage pathways are relatively few and small. The dead cells must travel upward, against gravity, to the lymph nodes in the armpit and upper chest (clavicle) before entering the vena cava and reaching the heart. This can cause inflammation if the dead cells are not fluid enough.
Fortunately for Bu Puspa, her tumor was located on the outer side (lateral), where there are better drainage pathways toward the armpit. Additionally, the dead cells were relatively fluid, making their disposal easier.
Bu Puspa underwent ultrasounds every three months to track her therapy’s progress. She was concerned that the new ECCT device might not deliver the desired results. It was a brave decision, but the challenge of eliminating the lump without surgery was a major motivation.
The ultrasound results every three months showed the tumor size gradually decreasing. Initially, it was almost 3 cm, then reduced to 2.3 cm after one year, and to 1.2 cm after 1.5 years. However, around the 1.5-year mark, Bu Puspa noticed through palpation that the large lump seemed to break into smaller nodules, some moving toward the armpit and others near the nipple. This phenomenon doesn’t occur with chemotherapy, which puzzled the radiologist. The doctor suspected it was a sign of metastasis.
However, if it was metastasis, the overall mass had shrunk, and the tumor on the ultrasound appeared similar to the surrounding tissue (isoechoic), making it difficult to conclude that it was metastasis using conventional radiology.
From an ECCT therapy perspective, based on physics, this is normal. The dead cancer cells, which turn into a mucus-like fluid, travel slowly through the bloodstream toward the armpit. During this process, the dead cells can accumulate and form clumps, which appear as new nodules on an ultrasound.
To ease her worries, Bu Puspa underwent a PET scan. The results showed that the active tumor had shrunk to 1 cm, and the smaller surrounding nodules were inactive, confirming that they were dead cells, consistent with the explanation she received from Dr. Warsito.
She continued her ECCT therapy. However, the PET-CT scan revealed an active nodule in her thyroid, a 4-5 cm fibroid in her uterus, and a liver cyst. It seemed like she was battling a full array of health issues.
Bu Puspa then underwent a hysterectomy, and her thyroid was covered by an additional ECCT device. She still refused conventional medical procedures for her thyroid, believing more in the progress she’d seen with ECCT.
After two years, the tumor in her breast shrank to less than 1 cm, and after three years, it was no longer detectable by ultrasound. The cyst in her left breast also disappeared. Though some ultrasounds occasionally detected small nodules or cysts, she was fully declared cancer-free after five years. Her thyroid nodule also became undetectable.
Even after being declared cancer-free, Bu Puspa continued using the ECCT device as a preventive measure and underwent regular ultrasound checkups. However, during the pandemic, she stopped her ultrasound exams and device checkups. Then, in mid-2022, after receiving multiple vaccinations, she began to feel a lump again in the same location and size as the one she had 9 years earlier.
An ultrasound confirmed a lump in her right breast at the same site as the previous one. However, its texture was different from the original lump, and a color Doppler ultrasound showed no vascularization (blood flow), suggesting the lump was inactive, possibly fibroglandular tissue with calcification.
How could there be a new but inactive lump of this size (3 cm)?
Dr. Warsito explained that during ECCT therapy, the cancer cells in the lump dissolve, but only the malignant cells. The tumor’s supporting tissue, composed of normal cells, remains. This tissue doesn’t revert to normal breast tissue but becomes fibrotic, like scar tissue.
Because this fibrotic tissue was damaged by the cancer cells, many blood vessels in the area are damaged and cannot function normally, leading to poor blood flow. This creates a situation where substances, such as vaccine particles, could accumulate in this area, forming a new lump.
To prevent further malignancy, Bu Puspa received the latest ECCT device, which includes a blanket and a new modulation program to kill malignant cells and help remove dead cells that accumulate in blood vessels.
After using the latest device for three months, Bu Puspa felt the lump fade and thin out. Once again, she understood the physical logic behind her condition.
Having been diagnosed with cancer 10 years ago, Bu Puspa remains healthy and active. She has rarely felt ill or burdened by her disease or therapy. Wishing continued good health for Bu Puspa (WS).
